Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentamicin for RDEB with Nonsense Mutations
NCT03012191Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Feb 2017
- Primary completion
- May 2018
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
- Countries
- 1
01
Overview
A Phase 2 trial of gentamicin in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by University of Southern California. Started Feb 2017; status: completed.
02
Drugs
gentamicin
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT03012191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012191.